MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients

Abstract

Soluble MUC1 has been discussed as a biomarker for predicting prognosis, treatment efficacy, and monitoring disease activity in breast cancer (BC) patients. Most studies in adjuvant settings have used preoperative assessment. This study, part of the SUCCESS-A trial (NCT02181101), assessed the prognostic value of soluble MUC1 before and after standard adjuvant chemotherapy. Patients with high-risk BC were treated within the SUCCESS-A trial with either three cycles of 5-fluorouracil, epirubicin, and cyclophosphamide followed by three cycles of docetaxel or three cycles of FEC followed by three cycles of docetaxel and gemcitabine. Cox regression analyses were performed to investigate the prognostic value of CA27.29 before and after chemotherapy relative to disease-free survival (DFS), along with established BC prognostic factors such as age, body mass index, tumor size, nodal status, estrogen receptor, progesterone receptor, HER2 status, and grading. Pre-chemotherapy and post-chemotherapy CA27.29 assessments were available for 2687 patients of 3754 randomized patients. Pre-chemotherapy CA27.29 assessment was associated with DFS in addition to established prognostic factors. It had no prognostic value in node-negative patients, but there was a clear association in node-positive patients. Post-chemotherapy CA27.29 assessment did not add any prognostic value, either on its own or in addition to pre-chemotherapy CA27.29 assessment.

CXC ELR-Positive Chemokines as Diagnostic and Prognostic Markers for Breast Cancer Patients

“…The biochemical diagnosis of breast cancer has mostly supportive applications and generally uses cancer antigen 15-3 (CA 15-3), cancer-embryonic antigen (CEA), and cancer antigen 27.29 (CA 27.29) [ 15 , 16 , 17 , 18 ]. However, the previously mentioned low sensitivity and specificity of these compounds preclude their use in screening [ 19 , 20 ].…”

Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies

“…It can also be assumed in further follow-up that an indication for active disease can be beneficial. With tumour markers and circulating tumour cells, it has already been shown that even 2 years after the primary diagnosis, a further classification into prognostic groups is possible [62,63].…”

“…Auch in der weiteren Nachsorge kann davon ausgegangen werden, dass eine Indikation für eine aktive Erkrankung von Nutzen sein kann. Mit Tumormarkern und zirkulierenden Tumorzellen ist bereits gezeigt worden, dass auch 2 Jahre nach der Primärdiagnose eine weitere Einteilung in prognostische Gruppen möglich ist [62,63].…”

Use of S2.2/DOX Magnetic Nanoliposomes in MR Molecule Imaging and Targeted Thermochemotherapy for Breast Cancer In Vitro

“…Mucin 1 (MUC1) is a transmembrane protein specifically and highly expressed in various BC tissues. 11 – 13 MUC1 plays a crucial role in the development and prognosis of BC, 14 making it an important target for imaging and therapeutic interventions in BC. 15 Nucleic acid aptamers (Apts) are short oligonucleotide fragments, including single-stranded DNA or small molecule RNA, which have shown great potential for targeted diagnosis and treatment of tumors.…”